Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

600196

Classement en actions #2196
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical... Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Prix de l'action
$3.40
Capitalisation boursière
$9.07B
Changement (1 jour)
-1.61%
Changement (1 an)
-16.08%
Pays
CN
Échange Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)

Catégorie

Healthcare
Bénéfices pour Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Shanghai Fosun Pharmaceutical (Group) Co., Ltd., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Shanghai Fosun Pharmaceutical (Group) Co., Ltd. de 2001 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2025 $730.66M 27.92%
2024 $571.20M 23.86%
2023 $461.19M -30.46%
2022 $663.16M -30.25%
2021 $950.72M 32.77%
2020 $716.07M 10.17%
2019 $649.94M 24.89%
2018 $520.40M -16.64%
2017 $624.28M 21.36%
2016 $514.42M -0.93%
2015 $519.24M 18.33%
2014 $438.82M 15.05%
2013 $381.42M 12.03%
2012 $340.46M 24.30%
2011 $273.89M 50.41%
2010 $182.10M -61.92%
2009 $478.18M 290.45%
2008 $122.47M 18.23%
2007 $103.59M 135.84%
2006 $43.92M 31.65%
2005 $33.36M 92.26%
2004 $17.35M -58.15%
2003 $41.46M 96.02%
2002 $21.15M 8.96%
2001 $19.41M 0.00%
Bénéfices des entreprises similaires ou concurrentes